Is there a pathway for phosphatidylinositol 3-kinase delta inhibitors to be approved therapeutics for B-cell lymphoma therapy Editorial
| Authors: | Luttwak, E.; Smith, M. R.; Zelenetz, A. D. |
| Title: | Is there a pathway for phosphatidylinositol 3-kinase delta inhibitors to be approved therapeutics for B-cell lymphoma therapy |
| Keywords: | rituximab; drug development; safety; pi3k; non-hodgkin lymphoma; double-blind; refractory; chronic lymphocytic-leukemia; combination; relapsed; idelalisib; phase-3; copanlisib; pi3k inhibitors; pi3k-delta; fda approval; clinical trial endpoints; indolent b cell lymphoma |
| Journal Title: | Expert Opinion on Pharmacotherapy |
| Volume: | 24 |
| Issue: | 12 |
| ISSN: | 1465-6566 |
| Publisher: | Informa Healthcare |
| Date Published: | 2023-01-01 |
| Start Page: | 1331 |
| End Page: | 1334 |
| Language: | English |
| ACCESSION: | WOS:001007456800001 |
| DOI: | 10.1080/14656566.2023.2223963 |
| PROVIDER: | wos |
| PUBMED: | 37294016 |
| Notes: | Editorial Material -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
